PhD: The University of Hong Kong, 1997
Post-doctoral Fellow: University of California, San Francisco, 2000
Senior Research Scientist, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia
Distinguised Scientist, Department of Experimental Therapeutics, BC Cancer Agency
Dr. Yuzhuo Wang (王玉琢) has a dual appointment as a Senior Research Scientist at the Vancouver Prostate Centre and Distinguished Scientist at the BC Cancer Agency. He is also the Founder of the Living Tumor Laboratory (www.livingtumorlab.com) and a Professor in Department of Urologic Sciences at UBC. Dr. Wang did his Ph.D. at the University of Hong Kong, and joined Dr. Gerald R. Cunha at University of California, San Francisco as a postdoctoral fellow in 1997. Since then, he has authored/co-authored over 120 peer-reviewed original articles and review papers with over 700 cumulative impact factors, including publications in Cancer Research, PNAS, Cancer Cell, Clinical Cancer Research, the EMBO Journal, and Nature. As a principal investigator, he is well funded by a number of agencies (e.g., the Canadian Institutes of Health Research).
Dr. Wang’s academic contributions can be highlighted by a number of novel hypotheses he has proposed, such as hypotheses on “prostate stem cells”, “epithelial-immune cell transition (EIT)”, “cancer-generated lactic acid is critical, immunosuppressive metabolite rather than a ‘waste product’ (which has been believed for more than 90 years)” and “tumour dormancy is a non-genetic disease”. Dr. Wang is recognized for his pioneering work in the field of prostate cancer modeling. He was the first to establish tissue recombination model of hormonal prostatic carcinogenesis. He also developed the first model of hormonal carcinogenesis in human prostatic epithelium. Moreover, he is responsible for a novel method for establishing transplantable, patient-derived xenograft models that closely resemble patients’ malignancies. Using the methodology, his group has developed over 200 transplantable patient-derived xenograft models in the laboratory. Importantly such “next generation” xenograft models have been effectively applied in a number of research areas, such as (i) preclinical drug efficacy studies in anti-cancer therapeutics development, (ii) discovery and validation of potential biomarkers and/or therapeutic targets, and (iii) personalized cancer therapy.
Dr. Wang has received numerous awards for his academic achievements in cancer research, such as a Prostate Cancer Foundation Research Award (2007), the Translation Research Award from Roche (2009), an Overseas Chinese Scholars Award from the National Natural Science Foundation of China (2009), the Innovative Scholar Award from the International Cancer Alliance for Research and Education (ICARE) (2010), UBC Faculty of Medicine Distinguished Achievement Award (2011), UBC Department of Urologic Sciences Outstanding Academic Performance Award (2013), Distinguished Visiting Professorship under the Tianjin Thousand Talents Program (2013) and UBC Department of Urologic Sciences Research Teaching Award (2015).